Abstract: The present invention relates to a peptide derived from the Helicobacter pylori ribosomal protein L1, and the use of this peptide an antibiotic. More specifically, the peptide is derived by making site-specific substitution mutations in a peptide consisting of amino acids 2-20 of the Helicobacter pylori ribosomal protein L1. The resulting peptide has both antibacterial activity and anti-inflammatory activity, but no cytotoxicity.

Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.

Abstract: Methods and compositions for inhibiting entry of an anthrax toxin and/or an anthrax toxin protein into a cell are provided. Aspects of the subject methods include administering to a host an effective amount of poly-?-Glutamic acid-Fe(III) chelate. Also provided are compositions suitable for use in the subject methods, as well as pharmaceutical preparations thereof.

Abstract: The present invention relates to methods and compositions for the treatment of retinal vein occlusion.

Abstract: A method of using a fertility enhancement food to improve human fertility. This fertility enhancement food consists of transfer factor, lactic acid generating bacteria, and/or glucans in appropriate combinations. The fertility food, administered correctly, reduces cortisol levels. High cortisol interferes with conception and stable pregnancies. Dosage amounts are adjusted for client weight. Consumption frequency may be adjusted in response to cortisol measurements. Typically, consumption of the fertility food begins seven or more days before planned conception.

Abstract: The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers.

Abstract: The present invention provides a method for inducing twin calving. The method according to the present invention comprises firstly treatment to inducing atresia of the antral follicles on ovary so as to initiate the development of new follicular wave, inducing the development of codominant follicles and further achieving double ovulations by exactly controlling the dosage and time points of hormone injections, and performing artificial insemination to induce the cow to deliver twin calves. The method according to the present invention has relative independent on the technical skills, and a person skilled in the art or a common worker can practice it according to specified operation methods; and during practical application, it does not require special equipment, thus saving cost, as well as improving the social benefit and economic benefit of cow breeding.

Abstract: The present invention pertains in general to the field of stabilization of FSH formulations, in particular liquid FSH formulations. The stabilization is achieved by the addition of salts comprising pharmaceutically acceptable alkali metal cations, in preferred embodiments by the addition of pharmaceutically acceptable salts, i.e. sodium salts or potassium salts.

Abstract: The present invention relates to a composition comprising Insulin Growth Factor I (IGF-I) or an analog thereof in combination with Insulin Growth Factor Binding Protein (IGFBP) or an analog thereof, said combination having a molar ratio of IGF-I to IGFBP 5 being lower than equimolar, preferably in the range from 1:20 to 1:3.33, for use in the treatment of a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth, as well as a method for treating a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth.

Abstract: The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.

Abstract: Methods and compositions are provided for increasing responsiveness to therapeutic metalloproteases including increasing and/or maximizing responsiveness and preventing botulinum and tetanus toxin resistance due to a functional deficiency of zinc. Also provided are methods for zinc replacement or supplement in lacking individuals comprising the administration of a zinc supplement for a loading period and/or administration of a phytase supplement together with the zinc supplement. Also provided are methods for standardization of botulinum toxin potency assays that provide for greater certainty and margins of safety in the use of products from different manufacturers.

Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.

Abstract: The present invention relates to a method of treating Stage IV melanoma in a subject. The method includes the step of administering to the subject a therapeutically effective amount of a melanoma cell lysate and/or an immunotherapeutic extract, component or antigen thereof.

Abstract: This invention provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.

Abstract: Modified protozoa parasites comprising simultaneous expression on its surface of at least two variable surface proteins (VSP). The modified protozoa may also simultaneously express the complete repertoire of variable surface proteins. Protozoa show reduced expression of Dicer, RNA-dependant RNA-polymerase (RdRP) enzymes or both, wherein the RdRP gene and/or the Dicer gene has been silenced. The protozoan may be any protozoan showing an antigenic variation mechanism.

Abstract: The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella. Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. Also provided are compositions including polypeptides having a particular molecular weight and a mass fingerprint that includes polypeptide fragments having a particular set of masses, or polypeptides having an amino acid sequence with at least about 95% identity with an amino acid sequence, wherein the polypeptide has seroreactive activity. The present invention also provides methods of making and methods of using such compositions.

Abstract: The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

Abstract: Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.

Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.

Abstract: African swine fever virus (ASFV) is the etiological agent of a contagious and often lethal viral disease of domestic pigs that has significant economic consequences for swine breeding. Control of ASF has been hampered by the unavailability of vaccines. Recombinant viruses harboring engineered deletions of specific virulence-associated genes induce solid protection against the challenge with parental viruses. Here we report the construction of a recombinant ?9GL virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate. In vivo, ASFV-G ?9GL administered intramuscularly (IM) to swine at relatively high doses (104 HAD50) retains a virulent phenotype practically indistinguishable from the parental virus. Conversely, at low IM doses (102 or 103 HAD50), ASFV-G ?9GL does not induce disease. Importantly, animals infected with 103 HAD50 are protected against the presentation of clinical disease when challenge at 28 days post infection with the virulent parental strain Georgia 2007.

Abstract: Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.

Abstract: A composition comprising the following composition: an AD vehicle including a synthetic peptide and a lipid, wherein the synthetic peptide includes the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20), a carboxylvinyl polymer and an RSV antigen. The composition has an antibody producing ability which is further higher than that of a conventional mucosal vaccine, hence capable of exerting excellent anti-virus antigen-specific IgA antibody- and IgG antibody-inducing effect in the nasal wash and the serum, respectively, even with an extremely small quantity of an RSV antigen.

Abstract: The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses.

Abstract: The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment C for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment C (TTC) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject.

Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.

Abstract: An improved method for the manufacture of an oil-in-water emulsion comprises using a microfluidization device whose interaction chamber comprises a plurality of Z-type channels upstream of a back pressure chamber.

Abstract: This invention is related to a stabilizing formulation for immunoglobulins G compositions comprising a sugar alcohol, glycine and a non-ionic detergent, which is suitable for the stabilization of immunoglobulins G compositions in liquid form and in lyophilized form. The invention also relates to an immunoglobulins G composition in liquid form or in lyophilized form comprising said stabilizing formulation.

Abstract: Disclosed herein are methods and compositions for reducing the recurrence of prostate cancer and for treating prostate cancer.

Abstract: The present disclosure is directed to an in-liquid laser-based method for fabricating a solution of fine particles of amorphous solid medicinal compounds, a solution of fine particles of amorphous medicinal agents made with the method, and fine particles made with the method. By using a target solidified via a phase transition process to covert an initial crystalline structure into an amorphous solid, technical difficulties with handling a hydraulically-pressed target are overcome. The laser-based ablation process produces amorphous solid medicinal compound fine particles, which improves the bioavailability and solubility of the medicinal compound. The improvement results from a combination of: disordered crystalline structure and enlarged relative surface area by particle size reduction. The laser based method may be carried out with ultrashort pulsed laser systems, or with UV nanosecond lasers.

Abstract: The present invention provides, among other things, multilayer film coating compositions, coated substrates and methods thereof. In some embodiments, a structure includes a substrate; and a multilayer film coated on the substrate, wherein adjacent layers of the multilayer film are associated with one another via one or more non-covalent interactions, wherein the multilayer film comprises a first nucleic acid agent present at a loading density, and further wherein the multilayer film is characterized in that, when the structure is placed on a subject so that the multilayer film contacts cells, the first nucleic acid agent is released with a profile characterized by a feature selected from the group consisting of 1) being a burst-free release; 2) being a sustained release; and 3) exhibiting in vitro and/or in vivo biological effectiveness.

Abstract: Provided is a platform for entrapment within alumina sol-gel carriers of labile biologically active materials such as proteins, therapeutic enzymes, enzymes of industrial relevance, antigens, and small molecules for achieving successful and efficient protective storage, protection from harsh environmental conditions such as heat, pH and chemicals, delivery to site and subsequent treatment and/or vaccination against diseases against which the active agents are targeted.

Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.

Abstract: The present invention relates to a cationic lipid of formula (I) having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

Abstract: A material including a continuous aqueous phase and a dispersed phase in the form of droplets containing an amphiphilic lipid and a surfactant having the following formula (I): (L1-X1—H1—Y1)v-G-(Y2—H2—X2-L2)w??(I), wherein: L1 and L2 independently represent lipophilic groups, X1, X2, Y1, Y2 and G independently represent a linking group, H1 and H2 independently represent hydrophilic groups including a polyalkoxylated chain, v and w are independently an integer from 1 to 8, wherein the droplets of the dispersed phase are covalently bonded by the surfactant having the formula (I). The invention also relating to the method for preparing the same and to the uses thereof.

Abstract: The present disclosure provides crystalline insulin-conjugates. The present disclosure also provides formulations, methods of treatment, methods of administering, and methods of making that encompass these crystalline insulin-conjugates.

Abstract: This application relates to methods for the purification of saccharide antigen-carrier protein conjugates. In particular, the invention provides a method for purifying saccharide antigen-carrier protein conjugates from free carrier protein, such as CRM1 97, using hydroxyapatite. The invention further relates to methods of preparing vaccines, using this method.

Abstract: The invention provides anti-ETBR antibodies and immunoconjugates and methods of using the same. In some embodiments, an immunoconjugate comprising an antibody that binds ETBR covalently attached to a cytotoxic agent is provided, wherein the antibody binds an epitope within amino acids 64 to 101 of SEQ ID NO: 10. In some embodiments, the cytotoxic agent is a nemorubicin derivative.

Abstract: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.

Abstract: Disclosed is a composition immunologically targeted to Alzheimer's disease (AD), the composition containing amine functionalized nanoparticles of Cerium oxide coated with polyethylene glycol and bearing an antibody specific for an amyloid-beta antigen associated with AD. The invention also includes a medication manufactured with the targeted nanoceria particles and methods of treatment by administering the targeted nanoceria particles to patients in need thereof.

Abstract: In some aspects, the present invention provides novel ligands, which may be used to make novel dual-modality imaging agents, for example, for PET and MRI imaging. In further aspects, by the present disclosure also provides methods of use and methods of preparation of the novel ligands, metal complexes, and imaging agents thereof.

Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue, suggesting favorable selective activity of compounds according to the present invention, which can be used as effective therapeutic agents against melanoma, including metastatic melanoma. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are useful to initiate therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic and therapeutic tools for a number of conditions and diseases states, especially melanoma.

Abstract: Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has one or more axial substituents.

Abstract: A device is disclosed for sterilizing objects, such as objects used during medical and dental procedures. A high velocity dry hot air sterilization device integrating a closed, sealed air handling system with a closed, sealed sterilization chamber is described. The sterilization device includes a chamber which carries a sealed instrument container. The sterilization device includes an air handling system for heating and adding velocity to the air which is delivered to the instrument container. The instrument container is configured to allow rapidly flowing hot air to enter from and exhaust to the closed air handling system within the high velocity dry hot air sterilization device without any infiltration of external air to the instrument container or to the high velocity dry hot air sterilizer's closed air handling system during the sterilization cycle, thereby preventing infiltration of microbial contaminants to the sterilization device or instrument container during or after sterilization.

Abstract: The shoe sole sanitizer provides a UV radiation emitting system that kills microbial pathogens deposited on shoe sole surfaces. The system includes a housing containing at least one UV radiation source. Bottom and side portions of the housing are opaque to provide a UV shield while directing the UV upward towards a top housing portion. The top housing portion has a plurality of holes forming an approximate shape of two shoe sole bottoms. The holes allow the UV radiation to escape the housing and target sole surfaces disposed on and over the exterior of the housing top. Each shoe sole approximation area has a pivotal tang that extends therefrom. Shutters attached internally to the tangs extend or limit UV exposure from the top surface depending on the size of the sole disposed on the top. The system is powered by standard AC electrical power or battery sources.

Abstract: A sterilizing apparatus provides a structure for feeding a sterilizer left in a vaporizing chamber configured to gasify the sterilizer, into a sterilizing chamber, to stimulate a sterilizing action while reducing waste of the sterilizer. The sterilizing apparatus includes a first atmosphere opening valve configured to perform an opening/closing operation to control communication between the atmosphere and the vaporizing chamber for vaporizing the sterilizer before the sterilizer is injected into the sterilizing chamber, and after a sterilizing gas vaporized in the vaporizing chamber is injected into the sterilizing chamber by vacuuming the vaporizing chamber with a vacuum pump, the vaporizing chamber and the atmosphere communicate with each other when the first atmosphere opening valve is opened while the vaporizing chamber and the sterilizing chamber communicate with each other.

Abstract: Medical devices having a wound closure device and a reinforcing material are reacted in situ to create a self-sealing implant.

Abstract: The presently-disclosed subject matter includes biodegradable scaffolds. Exemplary biodegradable scaffolds comprise a plurality of polythioketal polymers, and a plurality of polyisocyanates, where at least one polyisocyanate is linked to at least one polymer to form the scaffold. Thus, certain embodiments of scaffolds comprise a cross-linked network of the polythioketal polymers and the polyisocyanates. The presently-disclosed subject matter also includes methods for treating tissue, such as skin or bone tissue, in a subject in need thereof. Treatment methods comprise contacting the tissue with an effective amount of the biodegradable scaffold. Furthermore, the presently-disclosed subject matter includes methods for making the present biodegradable scaffolds.

Abstract: An object of the present invention is to provide a cell-adhesive material for biological tissues, in which the surface of a material for biological tissues (particularly metallic material) is modified strongly with a large amount of a cell-adhesive artificial peptide (P) that retains a biological activity. The present invention provides a cell-adhesive material for biological tissues including a cell-adhesive artificial peptide (P) and a material for biological tissues, wherein the cell-adhesive artificial peptide (P) is immobilized on the surface of the material for biological tissues through an electrochemical reaction. The cell-adhesive artificial peptide (P) is preferably a peptide (P1) that is synthesized by a genetic recombinant microorganism and has at least one cell-adhesive minimal amino acid sequence (X) in one molecule. The number of the cell-adhesive minimal amino acid sequences (X) in one molecule of the polypeptide (P1) is preferably 3 to 50.

Abstract: The present invention relates to methods for preparing bio scaffolds useful in the repair of tears. More specifically, the invention relates to a method of treating rotator cuff tear in a mammalian subject in need thereof comprising the steps of: (i) selectively expanding tenocytes in vitro in culture medium comprising insulin or a functional derivative and a glucocorticoid or a glucocorticoid-like molecule to produce a culture of expanded tenocytes; (ii) seeding a bioscaffold with said expanded tenocytes to produce a tenocyte seeded bioscaffold; and (iii) implanting said tenocyte seeded bioscaffold proximal to the rotator cuff tear. The present invention also relates to a bioscaffold comprising cells, wherein more than 80% of said cells are tenocytes.